Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
Scahill
Lawrence
L
Child Study Center, School of Medicine and School of Nursing, Yale University, New Haven, CT 06520, USA. lawrence.scahill@yale.edu
Blair
Jennifer
J
Leckman
James F
JF
Martin
Andrés
A
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003645:Death, Sudden; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D005879:Tourette Syndrome / Q000150:complications* / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D002784:Cholesterol